Patients with hereditary mutations in BRCA1 or BRCA2 (gBRCA1/2) and breast cancer have distinct tumor biology, and encompass a predilection for brain metastasis (BM). We looked into baseline risk of BMs among gBRCA1/2 patients. Patients with gBRCA1/2, stage I-III invasive breast cancer seen between 2000–2017 with parenchymal BMs. Among gBRCA1 with distant breast cancer recurrence, 34 of 76 (44.7%) were diagnosed with brain metastases compared to 7 of 42 (16.7%) patients with gBRCA2. In the comparator group, 65 of 182 (35.7%) noncarrier triple-negative breast cancer (TNBC) and a distant recurrence experienced BMs. In a competitive risk analysis using death as a competing factor, the cumulative incidence of BMs was similar between gBRCA1 and noncarrier TNBC patients. The time from primary breast cancer diagnosis to detection of BMs was similar between gBRCA1 and noncarrier TNBC patients (2.4 vs 2.2 years). Survival was poor after BMs (7.8 months for gBRCA1 patients vs. 6.2 months for TNBC noncarriers). Brain was a more common site of initial distant recurrence in gBRCA1 patients versus TNBC noncarriers (26.3% vs. 12.1%). Importantly, the presence of BMs, adversely impacted overall survival across groups (HR 1.68 (95% CI 1.12–2.53), hazard ratio for death if a patient had BMs at the time of initial breast cancer recurrence vs. not). In conclusion, breast cancer BMs is common and is similarly frequent among gBRCA1 and noncarrier patients with recurrent TNBC. Our study highlights the importance of improving the prevention and treatment of BMs in patients with TNBC, gBRCA1 carriers, and noncarriers.

npj Breast Cancer (2022)8:46 ; https://doi.org/10.1038/s41523-022-00407-z

INTRODUCTION

Hereditary pathogenic variants in the BRCA1 and BRCA2 genes substantially increase the risk of developing breast cancer, ovarian cancer, and other malignancies1. Pathogenic variants in either gene account for ~40% of hereditary breast and ovarian cancers and ~5% of total breast cancers2. Both genes function in the repair of double-strand DNA breaks through homologous recombination and operate as tumor suppressor genes. Hereditary pathogenic variants are typically heterozygous loss-of-function alterations3. The breast cancer phenotype associated with germline BRCA pathogenic variants (gBRCA) differs between gBRCA1 and gBRCA2, reflecting their disparate roles in homologous recombination. Breast cancer-associated with gBRCA1 is far more likely to be triple-negative breast cancer (TNBC), an aggressive subtype associated with a poor prognosis, whereas gBRCA2 breast cancers exhibit a similar receptor subtype distribution to sporadic breast cancers4.

Genetic testing for gBRCA is recommended for patients with metastatic breast cancer in whom it could help guide systemic therapy and for patients with any stage breast cancer who are considered to be at a high risk for hereditary breast cancer5. Genetic testing results inform breast cancer screening, risk reduction strategies, and family counseling, and they are now integral to the treatment of metastatic breast cancer. In 2018, the FDA approved the Poly (ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib for the treatment of HER2-negative, gBRCA-associated metastatic breast cancer. Both PARP inhibitors proved superior to chemotherapy in terms of progression-free survival (PFS) in phase III clinical trials that included metastatic breast cancer patients with gBRCA6-7. In the EMBRACA trial that evaluated talazoparib, ~15% of patients had brain metastases; however, to be eligible, patients with central nervous system (CNS) disease had to receive definitive local CNS therapy prior to the study. The investigators reported a comparable benefit of talazoparib in this subgroup of patients compared to the total population, though granular data on responses in the CNS were not provided in the initial report8. The combination of veliparib, carboplatin, and paclitaxel also demonstrated superior PFS versus placebo/carboplatin/paclitaxel in the Phase III BROCADE3 trial that included 509 patients with gBRCA1/2 and HER2-negative advanced breast cancer. In BROCADE3, patients with CNS disease composed ~5% of those enrolled and so they were not included as a separate subgroup9.

The prospect of improved systemic disease control with PARP inhibitors and emerging related therapies led us to ask whether we might observe more frequent CNS metastases among patients with gBRCA in the future, particularly if a propensity for brain metastasis exists in this patient subgroup9-12. This phenomenon has been observed in patients with metastatic HER2-positive breast cancer as tremendous advances have been made in treating systemic disease but effective treatments for CNS metastasis have lagged. Recently, clinical trials allowing enrollment of patients with untreated brain metastases have led to the approval of drugs like tucatinib, which demonstrated clear CNS activity13-15. Data regarding PARP inhibitor penetration of the blood-brain barrier (BBB) are mixed and likely relate to the extent and location of CNS metastases and the associated disruption of the BBB16-18.

The goal of this study was to determine the incidence of brain metastasis in gBRCA patients presenting with early-stage breast
RESULTS
Between 2000 and 2017, we identified 473 patients with gBRCA1 and 318 patients with gBRCA2 who were evaluated for stage I-III breast cancer at MDACC and who were captured in the clinical cancer genetics database. The median length of follow-up for the gBRCA1 and gBRCA2 patients was 9.15 years and 8.45 years, respectively. A total of 76 of 473 (16.1%) gBRCA1 patients and 42 of 318 (13.2%) gBRCA2 patients experienced a distant metastasis from breast cancer (Fig. 1). At 3 years, distant metastasis-free survival was inferior in gBRCA1 patients compared to gBRCA2 patients (86.7%) (95% confidence interval [CI], 83.2–90) vs. 94% (95% CI, 90.6–96.1); however, the Kaplan–Meier curves did not differ significantly overall (P = 0.25 by log-rank).

Brain metastases were diagnosed in 34 of 76 (44.7%) gBRCA1 patients with distantly recurrent disease and in 7 of 42 (16.7%) gBRCA2 patients with distantly recurrent disease. As expected, the gBRCA1 patients with distant metastasis had predominantly TNBC (77.6%, Table 1) whereas gBRCA2 patients had primarily HR-negative/HER2-negative disease (71.4%). Of the 34 gBRCA1 patients with eventual brain metastasis, 33 had TNBC, and 1 had HR-positive/HER2-negative primary breast cancer, though this patient’s disease lost ER/PR expression at the time of distant recurrence. Since the gBRCA1 cohort had the higher incidence of brain metastases and primarily TNBC, gBRCA noncarriers with TNBC and distant metastasis were utilized as the comparator group.

Breast cancer was diagnosed at a younger age in gBRCA1 patients compared to gBRCA2 patients and noncarriers (median age 38 vs. 44.8 vs. 47, P < 0.0001). The median time to genetic testing was shorter in gBRCA1 patients than in gBRCA2 patients and noncarriers (median 3.1 vs. 10.3 vs. 8.1 months, P = 0.029).

Diagnosis of a second primary breast tumor occurred in 5 of 76 (6.5%) gBRCA1 patients, 5 of 42 (11.9%) of gBRCA2 patients, and 13 of 182 (7.1%) of noncarriers. Additional patient and disease characteristics including patient race, cancer stage, tumor grade, and tumor histology are listed in Table 1.

Most patients had a mastectomy for surgical resection of the primary breast tumor, though approximately 20% or more of patients in each group had a partial mastectomy (Table 2). Systemic chemotherapy was administered for the primary breast cancer in the majority (>80%) of cases. More than half of patients in the gBRCA1 and noncarrier groups received neoadjuvant chemotherapy, reflecting the preference for upfront chemotherapy for TNBC. Chemotherapy was largely anthracycline-based across groups.

For the 106 patients who eventually developed brain metastases, the median time to the detection of brain metastases from the initial breast cancer diagnosis was similar between gBRCA1 patients and noncarriers (2.4 and 2.2 years) and was longer for gBRCA2 patients (5 years), though this was not statistically significant owing to the small size of the gBRCA2 cohort (Table 3). Among the 7 gBRCA2 patients who developed eventual brain metastases, all were female, 2 patients had HER2+ disease, and the remaining 5 patients had HR+/HER2-negative disease. All 7 patients received adjuvant chemotherapy for the primary breast tumor and 6 of 7 (85.7%) received adjuvant radiation. Due to the small number of gBRCA2 patients with brain metastases, we focused on estimating the cumulative incidence of brain metastasis among gBRCA1 patients and noncarriers with a distant recurrence.

Using death as a competing risk factor, the cumulative incidence of brain metastasis for gBRCA1 patients at 2 and 5 years from initial diagnosis was 17.2% (95% CI = 9.7–26.5%) and 38.8% (95% CI = 27.7–49.1%), respectively, compared to 15.4% (95% CI = 10.6–21.1%) and 33.3% (95% CI = 26.4–40.3%) for noncarriers (Fig. 2). In the competitive risk analysis, the cumulative incidence of brain metastasis was not different between the gBRCA1 and noncarrier cohorts (P = 0.263 by Gray’s test).

The brain parenchyma was a more frequent site of initial recurrence in gBRCA1 patients versus noncarriers (20/76 [26.3%] vs. 22/182 [12.1%, P = 0.01 by Fisher’s exact test between the two groups). Brain metastases were diagnosed as the initial recurrence in the absence of extracranial disease (i.e., isolated brain parenchymal metastases) in 11 of 20 gBRCA1 patients and 9 of 22 noncarriers. Among patients with brain metastasis, approximately one-third of gBRCA1 and noncarrier patients had a solitary brain metastasis whereas 13 of 34 (38.2%) gBRCA1 patients, 6 of 7 (85.7%) of gBRCA2 patients, and 32 of 65 (49.2%) noncarriers had more than three brain metastases on the initial brain MRI.

The treatments administered for brain metastasis included whole-brain radiotherapy (WBRT), stereotactic radiosurgery or radiotherapy (SRS/SRT), and surgical resection. There were no large differences in the modalities selected for gBRCA1 patients versus noncarriers. The median overall survival (OS) from the time of brain metastasis detection was uniformly poor: 7.8 months in gBRCA1 patients, 26.6 months in gBRCA2 patients, and 6.2 months in noncarriers (Fig. 3).

The presence of brain metastasis, irrespective of its timing, adversely impacted OS (Fig. 4 and Supplementary Figure 1). For example, the 45 patients who had brain metastases detected at the time of first recurrence had a median OS of 2.5 years compared to 3.4 years for patients who did not have brain metastases at the time of initial recurrence (HR 1.68, 95% CI 1.12–2.53). A similar trend was seen within the gBRCA1 cohort (Supplementary Figure 2).

Lastly, we assessed potential clinical predictors of brain metastasis among gBRCA1 and noncarrier patients in a multivariable logistic regression model. Univariate analyses were performed and variables with P ≤ 1 (breast cancer subtype, presence of a second primary breast tumor, tumor grade, adjuvant radiation) were then included in a multivariable model (Table 4; Supplementary Tables 1a/1b). In the multivariable model, TNBC was associated with higher rates of brain metastasis versus other breast cancer subtypes, which was expected and biased by our
inclusion of noncarriers with TNBC only. Importantly, the model produced similar results with the breast cancer subtype variable removed (Supplemental Table 2). In addition, the odds ratio for brain metastasis among patients having received prior adjuvant radiation for a primary breast cancer versus no adjuvant radiation was 2.3 (95% CI 1.26–4.19, P = .0066).

**DISCUSSION**
Our study of breast cancer patients with hereditary pathogenic variants in *gBRCA1* or *gBRCA2* revealed a high frequency of brain metastasis among women with distantly recurrent breast cancer and *gBRCA1*. There was no difference in predilection to extra cranial metastasis between *gBRCA1* or *gBRCA2* but revealed less incidence and longer time to brain metastasis of the tumors that are *gBRCA2* mutated compared to those that are *gBRCA1* mutated or non BRCA mutated TN breast cancer tumors. Among *gBRCA1* patients diagnosed with stage I-III breast cancer, 76 of 473 (16%) patients experienced a distant recurrence, and 34 of these 76 (44.7%) patients were diagnosed with brain metastases. The frequency of brain metastasis among *gBRCA2* patients with a distant recurrence was lower, with brain metastases detected in 7 of 42 (16.7%) *gBRCA2* patients in our cohort. As a comparator group for the *gBRCA1* cohort, we utilized patients diagnosed with

| Clinical characteristic | BRCA Status |       |       |       |       |
|-------------------------|-------------|-------|-------|-------|-------|
|                         |  *BRCA1* pathogenic variant *(n = 76)* |  *BRCA2* pathogenic variant *(n = 42)* |  *BRCA1*/2 non-carrier with TNBC *(n = 182)* |       |
| Median age at diagnosis (range) | 38 (23–72) | 44.8 (27–76) | 47 (19–79) | <0.0001 |
| Median time from diagnosis to hereditary genetic testing (IQR) in months | 3.1 (0.8–16) | 10.3 (1.2–114.1) | 8.1 (1.8–28.1) | 0.029 |
| Sex | 76 | 39 | 182 | 100 |
| Race | 41 | 32 | 118 | 64.8 | <0.0001 |
| Male | 15 | 3 | 7.1 |
| Asian/Pacific Islander | 5 | 4 | 3.3 |
| Other | 2 | 3 | 1.6 |
| TNBC | 59 | 4 | 9.5 | 97.8 | <0.0001 |
| HR-positive/HER2-negative | 8 | 30 | 71.4 |
| HER2-positive | 3 | 5 | 11.9 |
| HR-negative/HER2 unknown | 2 | 3 | 7.1 |
| Unknown | 2 | 2.6 |
| 2nd primary breast cancer | 5 | 5 | 11.9 | 7.1 | 0.532 |
| Stage (anatomic) | 16 | 11 | 26.2 | 18 | 9.9 | 0.027 |
| 2 | 29 | 18 | 42.9 | 91 | 50.0 |
| 3 | 29 | 13 | 31.0 | 73 | 40.1 |
| Unknown | 2 | 2.6 |
| Tumor grade | 3 | 3.9 | 2 | 1.1 | <0.0001 |
| 2 | 12 | 20 | 47.6 | 18 | 9.9 |
| 3 | 56 | 20 | 47.6 | 157 | 86.3 |
| Unknown | 5 | 2 | 4.8 | 5 | 2.7 |
| Histology | 71 | 36 | 85.7 | 163 | 89.6 | <0.0001 |
| IDC | 1 | 5 (mixed IDC/ILC) | 11.9 | 4 (3 are mixed IDC/ILC) | 2.2 |
| ILC | 3 | 9 | 2.4 | 15 | 8.2 |
| Other or breast cancer, NOS | 1 | 1 | 1 |
| Unknown | 1 | 1.3 |

*For patients with a second primary breast cancer, the most recent subtype is listed.*
stage I-III TNBC with recurrent breast cancer who had tested negative for variants in \textit{BRCA1} and \textit{BRCA2}. In a competitive risk analysis using death as a competing risk factor, the cumulative incidence of brain metastasis did not differ between \textit{gBRCA1} patients and TNBC noncarrier patients. In addition, the time from primary breast cancer diagnosis to the detection of brain metastasis was similar between \textit{gBRCA1} patients and TNBC noncarriers. In addition, the time from the radiation itself on residual tumor cells. Our multivariable model did not consider variables such as tumor stage/nodal stage, proliferation index (Ki-67), margin status, and lymphovascular invasion, which may explain why the adjuvant radiation variable was significantly associated with brain metastasis in our model.

Patient survival after the detection of brain metastasis was expectedly poor across subgroups and was only 7.8 months for \textit{gBRCA1} patients and 6.2 months in TNBC noncarriers. Survival after brain metastasis was longer in \textit{gBRCA2} patients (2.2 years), though interpretation of these data is limited by the small cohort size (\(n = 7\) patients). Brain metastasis had an adverse impact on survival in comparison to other sites of distant metastasis when considered as an initial event or at any time during the disease course.

We were interested in the baseline risk of brain metastasis among \textit{gBRCA1} and \textit{gBRCA2} patients in the pre-PARP inhibitor era to serve as context for evaluating CNS recurrences and responses now that PARP inhibitors and PARP inhibitors combinations are increasingly utilized in the adjuvant and metastatic settings\(^9\). PARP inhibitors improve systemic disease control and progression-free survival (an OS benefit has not been shown) versus standard chemotherapy, including in patients with treated brain metastases; however, their overall efficacy in the CNS remains uncertain. Two other institutions have reported their experience with \textit{gBRCA} breast cancer patients and CNS recurrence. The Dana Farber Cancer Institute (DFCI)/Beth Israel Deaconess Medical Center (BIDMC) \textit{gBRCA} cohort has been the focus of several important reports\(^{10,11,20}\). 

Lee et al. studied 46 \textit{gBRCA1} and 71 \textit{BRCA1/2} noncarrier early-stage breast cancer patients who had received alkylating chemotherapy and found that the rate and distribution of distant metastasis and OS was similar between the two groups\(^{20}\). They reported a potential propensity for brain metastasis among \textit{gBRCA1} patients (7 of 12 [58%] \textit{gBRCA1} patients with brain metastasis vs. 5 of 21 [24%] noncarriers), which they examined in further detail in a follow-up report. This study included additional patients (a total of 89 \textit{gBRCA1} and 175 noncarriers) and again compared the clinical outcomes of early-stage breast cancer patients treated with chemotherapy based on \textit{gBRCA1} status, limiting the analyses to the TNBC subtype. No difference was observed between the two groups in terms of recurrence site, freedom from distant metastasis, or breast cancer-specific survival. The frequency of brain metastasis in \textit{gBRCA1} patients with a distant breast cancer recurrence in this study was 7 of 19 (36.8%)

\begin{table}[h]
\centering
\begin{tabular}{|l|c|c|c|c|c|}
\hline
\textbf{BRCA Status} & \textbf{germline \textit{BRCA1} pathogenic variant} & \textbf{germline \textit{BRCA2} pathogenic variant} & \textbf{\textit{BRCA1/2} noncarrier with TNBC} & \textbf{\textit{P}} \\
\hline
\textbf{(n = 76)} & \textbf{(n = 42)} & \textbf{(n = 182)} & \\
\hline
\textbf{No. of Patients} & \textbf{\%} & \textbf{\%} & \textbf{\%} \\
\hline
\textbf{Surgery type} & & & & \\
Partial mastectomy & 16 & 21 & 8 & 19 & 66 & 36 & 0.04 \\
Mastectomy & 57 & 75 & 34 & 81 & 112 & 62 \\
ALND only for occult breast primary & 0 & 0 & 0 & 0 & 2 & 1 \\
Unknown & 3 & 4 & 0 & 0 & 2 & 1 \\
\hline
\textbf{Chemotherapy} & & & & \\
Neoadjuvant & 40 & 53 & 15 & 36 & 97 & 53 & 0.0001 \\
Adjuvant & 13 & 17 & 16 & 38 & 66 & 36 \\
No chemotherapy & 14 & 18 & 7 & 17 & 5 & 3 \\
Neoadjuvant + adjuvant & 9 & 12 & 4 & 10 & 14 & 8 \\
\hline
\textbf{Chemotherapy regimen} & & & & \\
Anthracycline-based (non-taxane)\(^a\) & 12 & 17 & 8 & 21 & 27 & 14 \\
Anthracycline + taxane & 46 & 65 & 23 & 59 & 135 & 71 \\
Taxane based & 8 & 11 & 6 & 15 & 23 & 12 \\
else & 5 & 7 & 2 & 5 & 6 & 3 \\
\hline
\textbf{Radiation therapy} & & & & \\
Yes & 47 & 62 & 30 & 71 & 126 & 69 & 0.677 \\
No & 26 & 34 & 12 & 29 & 56 & 31 \\
Unknown & 3 & 4 & 0 & 0 & 0 & 0 \\
\hline
\end{tabular}
\caption{Treatment characteristics of patients with distantly recurrent breast cancer by germline \textit{BRCA} status.}
\end{table}

*For patients with a second primary breast cancer, the treatment for the most recent breast cancer is listed. 
\(^a\)These patients primarily received FAC chemotherapy.
Table 3. Characteristics of brain metastases in patients with distantly recurrent breast cancer by germline BRCA status.

| BRCA Status | germline BRCA1 pathogenic variant (n = 76) | germline BRCA2 pathogenic variant (n = 42) | BRCA1/2 noncarrier with TNBC (n = 182) | P |
|-------------|------------------------------------------|------------------------------------------|---------------------------------------|---|
| No. of Patients | % | No. of Patients | % | No. of Patients | % |
| Breast cancer brain metastases detected at any time during patient's course | | | | | 0.009 |
| Yes | 34 | 44.7 | 7 | 16.7 | 65 | 35.7 |
| No | 42 | 55.3 | 35 | 83.3 | 117 | 64.3 |
| Median time to detection of brain metastases (years from date of diagnosis, range) | 2.4 (0.7–31.9) | 4.98 (1.7–14.4) | 2.2 (0.5–6.5) | 0.12 |
| Was the brain a site of initial distant recurrence? | | | | | 0.058 |
| Yes | 20 | 26.3 | 3 | 7.1 | 22 | 12.1 |
| No, brain mets were found later in course | 14 | 18.4 | 4 | 9.5 | 43 | 23.6 |
| No brain mets | 42 | 55.3 | 35 | 83.3 | 117 | 64.3 |
| If brain mets were among the initial site(s) of distant recurrence, was extracranial disease absent or present at the time of recurrence? | | | | | 0.53 |
| Extracranial disease absent | 11 | 1 | 9 | 0.587 |
| Extracranial disease present | 9 | 2 | 13 |
| Number of brain metastases at time of initial detection (as a %age of patients w/brain metastasis) | | | | | 0.250 |
| solitary | 12 | 35.3 | 1 | 14.3 | 21 | 32.3 |
| 2–3 brain metastases | 8 | 23.5 | 5 | 11 | 16.9 |
| >3 brain metastases | 13 | 38.2 | 6 | 85.7 | 32 | 49.2 |
| unknown | 1 | 2.9 | 1 | 1 |
| Treatment for initial brain metastases* | | | | | |
| WBRT | 22 | 56.4 | 4 | 50 | 36 | 48.6 |
| SRS/SRT | 8 | 20.5 | 25 | 33.8 |
| Resection | 8 | 20.5 | 2 | 25 | 10 | 13.5 |
| Hospice | 1 | 2.6 | 2 | 25 | 3 | 4.1 |
| Unknown | | | | | |

*Many patients were treated with multimodality therapy (e.g., resection followed by either SRS or WBRT). All treatments administered for the patients’ initial presentation of brain metastases are listed.

Fig. 2 Cumulative incidence of brain metastasis. Estimates of the cumulative incidence of brain metastasis are shown for gBRCA1 patients (n = 76) and noncarriers with triple negative breast cancer (n = 182) diagnosed with stage I–III disease with subsequent distant recurrence.

Fig. 3 Overall Survival with brain metastasis. Overall survival from the time of brain metastasis detection for breast cancer patients by gBRCA status.
patients and was 11 of 40 (27.5%) for noncarriers. Our analysis of the MDACC cohort generally agrees with these data in demonstrating that the cumulative incidence of brain metastasis among gBRCA1 and TNBC patients is similarly high. When we modified the competitive risk analysis to include only gBRCA1 patients who had TNBC primary tumors (rather than other subtypes), the cumulative incidence of brain metastasis was significantly higher among gBRCA1 TNBC patients vs. noncarrier TNBC patients (Supplementary Figure 3).

In a recent analysis of the DFCI gBRCA cohort, the authors reported a frequency of CNS metastasis (including parenchymal and leptomeningeal disease) among patients with recurrent breast cancer of 16/30 (53%) in gBRCA1 patients, 16/32 (50%) in gBRCA2 patients, and 67/270 (25%) in noncarriers (including all breast tumor subtypes, >50% HR+/HER2-negative)\(^9\). In a multivariable model within their study, only gBRCA2 was significantly associated with CNS metastasis. The frequency of reported CNS metastasis in their gBRCA2 cohort was higher than in ours (16/32 (50%) vs. 7/42 (16.7%)). Both DFCI and MDACC are subject to referral bias though differences in the timing of referral may be one factor that explains the discrepancy. A second factor is that our primary event of interest was parenchymal brain metastasis rather than combined parenchymal brain metastasis/leptomeningeal disease. A third difference is that Song et al. relied on two databases, one that included only patients with recurrent breast cancer whereas we utilized one prospectively maintained database that included all patients referred for genetic testing. Lastly, the gBRCA2 cohorts were limited in size in both studies. With regard to the multivariable model in Song et al. that showed gBRCA2 as a risk factor for brain metastasis compared to noncarriers, our comparator group included only patients with TNBC, whereas gBRCA2 breast cancer is predominantly HR+, and so our data do not address that specific question. A smaller study from Gustave Roussy reported parenchymal brain metastasis among patients with distantly recurrent breast cancer in 10/15 (66.7%) gBRCA1 patients, 0/12 gBRCA2 patients, and 6/58 (10.3%) noncarriers (all breast tumor subtypes included)\(^8\). Taken together, these reports from the DFCI/BIDMC and Gustave Roussy along with our data from MDACC confirm a high rate of brain metastasis among gBRCA1 patients and noncarriers with TNBC.

Brain metastasis in gBRCA1 pancreatic cancer patients is case reportable and is similarly rare in metastatic prostate cancer\(^27-29\). Interestingly, increased homologous recombination deficiency (in wild-type BRCA1/2 tumors) has been observed among breast cancer brain metastases\(^30,31\). In one study that examined the molecular features of paired primary breast tumors/brain metastases, an increase in homologous recombination deficiency was observed in the brain metastasis compared to the primary tumor in 14/16 (87.5%) of the cases\(^30\). Similar data have been reported for colorectal cancer brain metastases\(^32\). The investigators hypothesize that higher levels of homologous recombination deficiency may enable tumor cells to adapt more readily to the CNS microenvironment. In a systematic review of the genetic landscape of breast cancer brain metastases, several genes involved in DNA damage repair were among the 22 most frequently altered genes in brain metastases, including BRCA1, BRCA2, MLH1, ATR, ATM, and CHEK2 whereas these genes were not among the most altered genes cataloged in extracranial distant recurrences\(^33-35\). Accordingly, two genes integral to homologous recombination, BARD1, and RAD51, were found to be overexpressed in breast cancer brain metastases compared to matched primary breast tumors, and when overexpressed in a human breast cancer cell line, these genes mediated increased brain metastases in mouse xenograft models\(^36\). No studies have focused exclusively on the molecular features of gBRCA brain metastases, and it would be interesting to determine whether these tumors undergo less genomic evolution upon CNS invasion since homologous recombination deficiency is intrinsic to the primary tumor. In addition, if TNBC tumors do become more BRCA-like upon seeding the brain, there is the possibility for therapeutic activity of PARP inhibitors with adequate CNS penetration. For example, it will be important to assess whether olaparib, as evaluated in the phase III OlympiA trial, was effective at preventing both systemic and CNS recurrences\(^37,38\).

Our study has several limitations. First, gBRCA patients with early-stage breast cancer have a good prognosis and, fortunately, distant metastasis is infrequent\(^39-41\). Of the 791 gBRCA early stage breast cancer patients that were followed longitudinally at MDACC, ~15% developed a distant recurrence, and the overall frequency of brain metastasis in the total gBRCA cohort was ~5%. As a result, our single-institution cohort of gBRCA patients with distantly recurrent breast cancer is small, though it is larger/ comparable to those from previous reports. Second, the true incidence of brain metastasis is unknown since routine brain MRI

![Graph showing overall survival with distant recurrence](image)

**Fig. 4 Overall Survival with distant recurrence.** Overall survival from the time of diagnosis for patients with recurrent breast cancer stratified by the presence or absence of brain metastases among the initial sites of disease recurrence.

**Table 4.** Multivariable logistic regression of potential clinical factors in brain metastasis (n = 258 gBRCA1 and non-carrier patients).

| Effect                        | Odds Ratio Estimates | 95% Wald Confidence Limits | p-value |
|-------------------------------|----------------------|----------------------------|---------|
| Tumor grade (III vs. I/II)    | 2.425                | 0.971 – 6.055              | 0.0579  |
| Breast ca subtype (others vs TNBC) | 0.082                | 0.01 – 0.636              | 0.0167  |
| Presence of a second primary tumor | 0.25                | 0.053 – 1.186              | 0.081   |
| Adj radiation (Yes vs. no)    | 2.296                | 1.261 – 4.181              | 0.0066  |
screening is not recommended and is typically reserved for symptomatic patients. Thus, the estimates we provide almost certainly underestimate the true incidence. Third, though the clinical genetics database at MDACC is prospectively maintained and routinely updated, our study is retrospective in its scope and there are many uncontrolled factors including date of gbRCA testing, receipt and type of chemotherapy, and length of follow-up. A minor fraction of patients in all groups were lost to follow-up. Nonetheless, the strengths of our study include its use of a single, large database with comprehensive clinical annotation and the manual verification of all clinical data reported. The MDACC genetics clinic is an active and longitudinal program, reflected by the ~9-year median length of follow-up for gbRCA patients. As a result, we believe the data provided in this report are representative of the larger gbRCA population.

In conclusion, brain metastasis is a similarly frequent event among gbRCA1 patients and gbRCA noncarriers with recurrent TNBC. In a competitive risk analysis from the time of primary breast cancer diagnosis, the 5-y cumulative incidence of brain metastasis among patients with recurrent breast cancer was 38.8% for gbRCA1 patients and 33.3% for noncarriers with TNBC ($P = 0.26$). Interestingly, studies of the molecular features of paired primary breast cancer/brain metastasis specimens, most of which are BRCA1/2 wild-type, suggest that breast cancer cells capable of CNS propagation have increased homologous recombination deficiency, a characteristic intrinsic to BRCA1/2-deficient tumors. The therapeutic efficacy of PARP inhibitors for the treatment or prevention of CNS recurrence in BRCA-mutant (hereditary or somatic) or BRCA wild-type breast cancer is largely unknown, though the currently approved PARP inhibitors are unlikely to mediate durable CNS responses as monotherapy. Our study aligns with prior reports and underscores the importance of improving the prevention and treatment of brain metastasis in patients with recurrent TNBC, both in gbRCA1 carriers and noncarriers.

**METHODS**

**Patient population and data collection**

Approval was obtained from the institutional review board at UT MD Anderson Cancer Center (MDACC, approval no. PA18-0386). A waiver of consent was obtained to ensure ethical standards of data use due to the retrospective nature of the study. To determine the incidence of brain metastasis among gbRCA patients and gbRCA noncarriers, we queried an IRB-approved, prospectively maintained electronic database that includes patients referred to the MDACC clinical cancer genetics program who underwent gbRCA testing. Patients who test positive for various germline mutations or negative (noncarriers) are included in the database. We identified patients within the database with stage I-III invasive breast cancer who were evaluated at MDACC between 2000-2017 and who tested positive for hereditary mutations in BRCA1 or BRCA2 and assessed for disease recurrence and parenchymal brain metastasis. Patients with variants of uncertain significance in gbRCA were excluded from the analysis. Patients with leptomeningeal disease (LMD) were considered to have distant metastasis but were not included in our parenchymal brain metastasis cohort unless they had disease in both sites. The comparator group included noncarrier patients diagnosed with stage I-II TNBC who experienced subsequent distant metastasis. Clinical data from this cohort were extracted from the same database. The number of noncarrier TNBC patients with stage I-II invasive breast cancer between 2000-2017 within the database was too large for manual confirmation of clinical variables and so we limited the analysis to the 182 patients with distant metastasis.

Data elements collected included: patient demographics [sex, date of birth, and race (self-reported at time of new patient registration)], date of primary breast cancer diagnosis, date of last known follow-up, date of death if applicable (abstracted from chart or using the US Social Security Death Index), presence or absence of a second primary breast malignancy, BRCA status, date of BRCA testing, and specific BRCA genetic alteration. Disease characteristics collected included: receptor subtype (estrogen receptor [ER]/progestere receptor [PR]/human epidermal growth factor receptor 2 [HER2]), anatomic stage (including T and N staging) at diagnosis, histologic subtype, tumor grade. Treatment characteristics collected included: type of surgery for primary breast cancer, chemotherapy delivered for primary breast cancer, distant recurrence and date if applicable, location of distant recurrence, and brain metastasis and date of detection if applicable. Brain metastasis characteristics and the treatment administered for the initial brain metastases were also abstracted from patients’ charts. Patients with Stage IV de novo metastatic disease were excluded.

Tumors were considered triple negative if both ER and PR were negative (<10% tumor staining) and HER2 was considered non-amplified. HER2 status was assessed by immunohistochemistry or fluorescence in situ hybridization when indicated and considered positive or negative on the basis of institutional cutoffs and guidelines that were current at the time of diagnosis. For tumor grade, composite histologic grade was used when available and if unavailable, nuclear grade was used. For patients with a second primary breast cancer, the most recent primary breast cancer was used in the analysis.

**Statistical analyses**

Continuous variables are reported as mean or median (and range or interquartile range [IQR]). The distribution of each categorical variable is summarized in terms of its frequency and percentage. Distant metastasis-free survival was defined as the time from primary breast cancer diagnosis to distant metastasis (bone, liver, lung, CNS parenchyma, non-regional lymph node, etc.) or death from any cause. Patients still alive at the time of analysis were censored at their last date of follow-up. Time to brain metastasis was computed from the date of diagnosis of the primary breast cancer to the date of detection of brain metastasis on imaging or last follow-up. The cumulative incidence of brain metastases was estimated by Fine-Gray competing risk approach, considering death as a competing risk. Among patients who developed brain metastasis, survival following brain metastasis was computed from the date of detection of brain metastasis to the date of death or last follow-up. Categorical data were compared using the X² or Fisher’s exact test. Continuous data were compared using Wilcoxon rank sum test (two groups) or Kruskal–Wallis test (three groups). All tests were two-sided and $P$ values < 0.05 were considered statistically significant as exploratory analyses. We used the Kaplan–Meier method to estimate survival and compared survival curves using the log-rank test. Computations were carried out using SAS version 9.4 and R 4.0.2 and GraphPad Prism 8.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Received: 29 September 2021; Accepted: 24 February 2022;
Published online: 07 April 2022

**REFERENCES**

1. Mavaddat, N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J. Natl Cancer Inst. 105, 812–822 (2013).
2. Cobain, E. F., Milliron, K. J. & Merajver, S. D. Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. Semin Oncol. 43, 528–535 (2016).
3. Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110–20 (2016).
4. Atchley, D. P. et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 26, 4282–4288 (2008).
5. National Comprehensive Cancer Network. Breast Cancer (Version 5.2020). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 22, 2020.
6. Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018).
7. Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017).
8. Diers, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BRoadCASe3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 1269–1282 (2020).
9. Albigès, L. et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: Highly increased incidence of brain metastases. Ann. Oncol. 16, 1846–1847 (2005).
10. Song, Y. et al. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer 126, 271–280 (2020).
11. Tung, N. et al. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Res. Treat. 146, 175–82 (2014).
12. Zavitsanos, P. J. et al. BRCA1 mutations associated with increased risk of brain metastases in breast cancer: A 1:2 matched-pair analysis. Am. J. Clin. Oncol. 41, 1252–1256 (2018).
13. Musolino, A. et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 117, 1837–1846 (2011).
14. Mounsey, L. A. et al. Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies. Clin. Breast Cancer 18, 29–37 (2018).
15. Murthy, R. K. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. 382, 597–609 (2020).
16. Exman, P. et al. Response to Olaparib in a patient with Germline BRCA2 mutation and breast cancer leptomeningeal carcinomatosis. NPJ Breast Cancer 5, 46 (2019).
17. Kizilbash, S. H. et al. Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on Temozolomide Therapy in Glioblastoma. Mol. Cancer Ther. 16, 2735–2746 (2017).
18. Karginova, O. et al. Efficacy of Carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild type triple-negative breast cancer. Mol. Cancer Ther. 14, 920–30 (2015).
19. Tutt, A. N. J. et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394–2405 (2021).
20. Lee, L. J. et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 117, 3093–3100 (2011).
21. Borella, F. et al. Brain metastases from ovarian cancer: current evidence in diagnosis, treatment, and prognosis. Cancers 12, 2156 (2020).
22. Gourley, C. et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J. Clin. Oncol. 28, 2505–2511 (2010).
23. Sekine, M. et al. Increased incidence of brain metastases in BRCA1-related ovarian cancers. J. Obstet. Gynaecol. Res. 39, 292–296 (2013).
24. Stasenko, M. et al. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecol. Oncol. 154, 144–149 (2019).
25. Ratner, E. et al. Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecol. Oncol. 153, 568–573 (2019).
26. Balendiran, S. et al. Next-generation sequencing-based genomie profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. J. Neurooncol. 133, 469–476 (2017).
27. Sonnenblick, A. et al. Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report. Mol. Clin. Oncol. 8, 683–685 (2018).
28. Jordan, E. J. et al. Brain metastases in pancreatic ductal adenocarcinoma: assessment of molecular genotype-phenotype features-an entity with an increasing incidence?. Clin. Colorectal Cancer 17, e315–e321 (2018).
29. Patel, M. et al. Clinical, genetic, and pathologic determinants of prostate cancer brain metastasis. J. Clin. Oncol. 38, 5536–5536 (2020).
30. Diossy, M. et al. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann. Oncol. 29, 1948–1954 (2018).
31. Tyran, M. et al. A comparison of DNA mutation and copy number profiles of primary breast cancers and paired brain metastases for identifying clinically relevant genetic alterations in brain metastases. Cancers 11, 5 (2019).
32. Sun, J. et al. Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. Nat. Commun. 10, 3190 (2019).
33. Morgan, A. J., Giannoudis, A. & Palmieri, C. The genomic landscape of breast cancer brain metastases: a systematic review. Lancet Oncol. 22, e7–e17 (2021).
34. Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560–564 (2019).
35. Angus, L. et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450–1458 (2019).
36. Woditschka, S. et al. Woditschka, S. et al. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J. Natl Cancer Inst. 106, 1–13 (2014).
37. Goncalves, A., Bertucci, A. & Bertucci, F. PARP inhibitors in the treatment of early breast cancer: the step beyond?. Cancers 12, 1378 (2020).
38. Hahnen, E. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 3, 1378–1385 (2017).
39. Bignon, L. et al. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Breast J. 24, 269–277 (2018).
40. Ancestry.com. U.S. Social Security Death Index, -A.J., 2020.http://www.ancestry.com/search/collections/ssdi/.
41. Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 1141–1154 (1988).

ACKNOWLEDGEMENTS

Presented as Poster at the ASCO, Chicago, 2020. This work was supported by Sheila Wynne Research Fund. The database is supported by the Nellie B. Connally Research Funds and the biostatistical effort was supported in part by the Cancer Center Support Grant (NCI Grant P30 CA016672).

AUTHOR CONTRIBUTIONS

Design/conception: B.A., H.R.G., N.K.L. Data collection: A.S.R., M.L., A.M.G., Statistical analysis: H.R.G., W.Q., Data interpretation: all authors. Manuscript writing: all authors.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41523-022-00407-z.

Correspondence and requests for materials should be addressed to Nuhad K. Ibrahim.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022